相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies et al.
CLINICAL CANCER RESEARCH (2014)
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Traditional Roles in a Non-Traditional Setting: Genetic Counseling in Precision Oncology
Jessica N. Everett et al.
JOURNAL OF GENETIC COUNSELING (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
Luc Friboulet et al.
CANCER DISCOVERY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
L04.04 * WINTHER: A STUDY TO SELECT RATIONAL THERAPEUTICS BASED ON THE ANALYSIS OF TUMOR AND MATCHED NORMAL TISSUE BIOPSIES IN SUBJECTS WITH ADVANCED MALIGNANCIES
J. C. Soria et al.
ANNALS OF ONCOLOGY (2013)
Real-time Liquid Biopsy in Cancer Patients: Fact or Fiction?
Klaus Pantel et al.
CANCER RESEARCH (2013)
Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial
Ben Tran et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges
Rodrigo Dienstmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Justin F. Gainor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Next-Generation Sequencing Reveals High Concordance of Recurrent Somatic Alterations Between Primary Tumor and Metastases From Patients With Non-Small-Cell Lung Cancer
Stephane Vignot et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Genetic Basis for Cancer Treatment Decisions
Janet E. Dancey et al.
CELL (2012)
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Apostolia-Maria Tsimberidou et al.
CLINICAL CANCER RESEARCH (2012)
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
Carsten Bokemeyer et al.
EUROPEAN JOURNAL OF CANCER (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Gopa Iyer et al.
SCIENCE (2012)
Intratumor Heterogeneity: Seeing the Wood for the Trees
Timothy A. Yap et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
Levi A. Garraway et al.
CANCER DISCOVERY (2012)
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
N. Knijn et al.
BRITISH JOURNAL OF CANCER (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer
Jeanette Dupont Jensen et al.
CLINICAL CANCER RESEARCH (2011)
Reasons given by patients for participating, or not, in Phase 1 cancer trials
S. Catt et al.
EUROPEAN JOURNAL OF CANCER (2011)
Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience
Hazem El-Osta et al.
ONCOLOGIST (2011)
Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
Sameek Roychowdhury et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
Luis Paz-Ares et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients withMetastaticBreast Colorectal and Prostate Cancer
M. Craig Miller et al.
JOURNAL OF ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pathobiology of ALK+ anaplastic large-cell lymphoma
Hesham M. Amin et al.
BLOOD (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Melanoma biology and new targeted therapy
Vanessa Gray-Schopfer et al.
NATURE (2007)
Cancer genes and the pathways they control
B Vogelstein et al.
NATURE MEDICINE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint
R Mick et al.
CONTROLLED CLINICAL TRIALS (2000)
分享论文
